Elsevier

Continuing On

German research institutes are still negotiating with academic publisher Elsevier over cost and open-access polices, Nature News reports.

Participants in the pilot will begin developing the capabilities required for the planned data commons, including making data transparent and interoperable.

Nature News reports that a US court has ordered paper-sharing sites to pay damages to publisher Elsevier.

The companies will integrate Elsevier's database of biological molecular interactions and curated pathways with the SolveBio operation system for molecular information.

Down to the Deadline

ScienceInsider says a consortium of German institutions and the publisher Elsevier are still working out a deal for journal access.

The integrated products will provide a seamless workflow for interpreting next-generation sequence data from alignment through pathway analysis.

The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio. 

Under the terms of the agreement, the companies will combine software products and data to improve NGS analysis and interpretation

This week, GenomeQuest launched a new Intellectual Property Management module for its software that lets customers manage their sequence IP.

NEW YORK (GenomeWeb) – Elsevier, a provider of scientific, technical, and medical information products and services, said this week that it has linked two of its databases to provide pharmaceutical companies with better risk monitoring and improved pharmacovigilance resources.

Pages

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.